SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after the National Comprehensive Cancer Network updated its clinical guidelines to include ANKTIVA for a broader range of bladder cancer patients, signaling a significant expansion of the drug's eligible treatment population. The community is buzzing over this potential catalyst for increased insurance coverage and revenue, while actively discussing the long-term outlook for the company's immunotherapy platform as it gains momentum in both clinical and international markets.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging following a massive five-year, $27 billion AI infrastructure deal with Meta, which builds on a recent $2 billion equity investment from Nvidia. The community is heavily focused on the company's rapid hyperscaler expansion, debating the implications of this contract for future revenue and whether the stock's valuation is poised for a sustained breakout or a potential pullback.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is currently trading in a tight consolidation range as investors weigh record-breaking revenue and strong AI infrastructure demand against margin compression concerns and lingering sentiment around historical accounting reports. The community is actively debating the company's long-term value, with many hopeful that upcoming industry conferences and strategic NVIDIA ecosystem partnerships will finally catalyze a breakout from the stock's multi-month sideways trend.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing significant operational headwinds as a prolonged government shutdown triggers mandatory flight capacity cuts and widespread cancellations, putting pressure on industry profit guidance. Despite these challenges, market sentiment remains cautiously optimistic as investors monitor the impact of rising fuel costs against the backdrop of robust travel demand and resilient corporate booking trends.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant investor attention due to a surge in trading volume and speculation regarding a potential short squeeze, fueled by its pivot toward stablecoin settlement and institutional infrastructure. The community is actively discussing recent corporate developments, including share dilution, and is keenly anticipating an upcoming Investor Day that many hope will clarify the company's long-term growth strategy.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple's XRP is trending as traders closely monitor its recent price action and resistance levels, with many community members debating whether the current move is a sustainable breakout or another manipulation trap. The conversation is heavily polarized between long-term holders citing institutional adoption and potential utility, and skeptics who remain wary of market volatility and its historical correlation with broader crypto movements.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and investor interest as the market anticipates potential product updates and partnership news at the upcoming OFC conference. Community discussion is heavily focused on the company's progress in scaling manufacturing for AI-driven optical interconnects, with traders debating whether upcoming industry events will provide the long-awaited catalyst for sustained price momentum.

Coda Octopus Group, Inc. engages in the developing, manufacturing, and marketing of subsea products. The firm operates through the following segments: Marine Technology Business (Products), Acoustics Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology Business segment develops solutions for subsea and underwater markets. The Acoustics Sensors and Materials Business segment engages in the provision of a comprehensive range of products and solutions, with a primary focus on medical imaging and Non-Destructive Testing. The Defense Engineering Services Business segment engages in defense contractors and designs, engineers, manufactures and supplies proprietary sub-assemblies for incorporation into broader mission critical defense systems. It also operates through the Americas, Europe, Australia or Asia, and Middle East or Africa geographical segments. The company was founded in 1994 and is headquartered in Orlando, FL.

Coda Octopus Group Inc.

Coda Octopus Group is gaining traction as investors focus on its proprietary real-time 3D sonar technology, which is increasingly critical for subsea infrastructure, defense, and maritime security. The community is actively discussing the stock's multi-bagger potential, high institutional interest, and the significant demand for its specialized equipment in global underwater operations.

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics is trending following a significant strategic reprioritization that includes a workforce reduction and the termination of several key partnerships, sparking intense debate among investors about the company's long-term viability and the status of its pipeline. The community is actively discussing the recent departure of high-level executives and the extended delays in critical data readouts, with many expressing frustration over the persistent decline in share price relative to their initial cash-backed valuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform Decoy Therapeutics Enters Strategic...

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split Decoy Therapeutics Announces 1-for-12 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., March 5, 2026 CAMBRIDGE, Mass., March 5, 2026...

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics Joins Webull Corporate Connect Service Platform Decoy Therapeutics Joins Webull Corporate Connect Service Platform PR Newswire CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 - Connect...

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial Decoy Therapeutics to Participate in the Corporate Connect Webinar Series...

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform Decoy Therapeutics Reaches Global...

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

DCOY
Decoy Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DCOY News

DCOYDecoy Therapeutics Inc.